Cargando…

Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy

[Image: see text] Cancer vaccine is well recognized as a promising approach for immunotherapy of cancers. Since dendritic cells (DCs) are capable of processing and presenting antigens to initiate the immune response cascade, the development of DC vaccines is considered as a good choice for the treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Hong, Shi, Hongyan, Fu, Peng, Shi, Pengfei, Yang, Jianyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876850/
https://www.ncbi.nlm.nih.gov/pubmed/33585776
http://dx.doi.org/10.1021/acsomega.0c05924
_version_ 1783650051324641280
author Pan, Hong
Shi, Hongyan
Fu, Peng
Shi, Pengfei
Yang, Jianyuan
author_facet Pan, Hong
Shi, Hongyan
Fu, Peng
Shi, Pengfei
Yang, Jianyuan
author_sort Pan, Hong
collection PubMed
description [Image: see text] Cancer vaccine is well recognized as a promising approach for immunotherapy of cancers. Since dendritic cells (DCs) are capable of processing and presenting antigens to initiate the immune response cascade, the development of DC vaccines is considered as a good choice for the treatment of cancer. Herein, a folic acid (FA)-modified liposome was constructed and loaded with chlorin e6 (Ce6) as a DC vaccine (FA-Lipo-Ce6). It was suggested that the loaded Ce6 within FA-Lipo-Ce6 can be activated under laser irradiation. The photodynamic therapy (PDT) of Ce6 was expected to create on-demand reactive oxygen species (ROS) in situ, which causes cell death and trigger the exposure of tumor-associated antigen (TAA). In addition, the produced ROS can mimic the inflammatory responses for the employment of DC for better antigen presentation and immune response. Most importantly, the employment of DC can recognize the exposed TAA to stimulate DC for effective vaccination in situ. Our results demonstrated the powerful capacity of FA-Lipo-Ce6 to induce DC activation, leading to effective suppression of the growth of breast cancers.
format Online
Article
Text
id pubmed-7876850
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-78768502021-02-12 Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy Pan, Hong Shi, Hongyan Fu, Peng Shi, Pengfei Yang, Jianyuan ACS Omega [Image: see text] Cancer vaccine is well recognized as a promising approach for immunotherapy of cancers. Since dendritic cells (DCs) are capable of processing and presenting antigens to initiate the immune response cascade, the development of DC vaccines is considered as a good choice for the treatment of cancer. Herein, a folic acid (FA)-modified liposome was constructed and loaded with chlorin e6 (Ce6) as a DC vaccine (FA-Lipo-Ce6). It was suggested that the loaded Ce6 within FA-Lipo-Ce6 can be activated under laser irradiation. The photodynamic therapy (PDT) of Ce6 was expected to create on-demand reactive oxygen species (ROS) in situ, which causes cell death and trigger the exposure of tumor-associated antigen (TAA). In addition, the produced ROS can mimic the inflammatory responses for the employment of DC for better antigen presentation and immune response. Most importantly, the employment of DC can recognize the exposed TAA to stimulate DC for effective vaccination in situ. Our results demonstrated the powerful capacity of FA-Lipo-Ce6 to induce DC activation, leading to effective suppression of the growth of breast cancers. American Chemical Society 2021-01-25 /pmc/articles/PMC7876850/ /pubmed/33585776 http://dx.doi.org/10.1021/acsomega.0c05924 Text en © 2021 The Authors. Published by American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle Pan, Hong
Shi, Hongyan
Fu, Peng
Shi, Pengfei
Yang, Jianyuan
Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy
title Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy
title_full Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy
title_fullStr Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy
title_full_unstemmed Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy
title_short Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy
title_sort liposomal dendritic cell vaccine in breast cancer immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876850/
https://www.ncbi.nlm.nih.gov/pubmed/33585776
http://dx.doi.org/10.1021/acsomega.0c05924
work_keys_str_mv AT panhong liposomaldendriticcellvaccineinbreastcancerimmunotherapy
AT shihongyan liposomaldendriticcellvaccineinbreastcancerimmunotherapy
AT fupeng liposomaldendriticcellvaccineinbreastcancerimmunotherapy
AT shipengfei liposomaldendriticcellvaccineinbreastcancerimmunotherapy
AT yangjianyuan liposomaldendriticcellvaccineinbreastcancerimmunotherapy